ArticleTherapeutic advances in infectious disease

Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.

Sandra Rajme-López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.